OR WAIT null SECS
According to the press release, it is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required.
908 Devices announced the launch of MAVERICK on Sept. 18, 2023, which is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures and supports large-scale efforts in predictive bioprocess modeling. According to the press release, it is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required.
In addition, MAVERICK offers the advantages of Raman spectroscopy without the cost and complexities associated with conventional spectroscopic methods, according to the press release. The device’s de novo models process Raman spectra from a wide variety of culture media types and cell lines, which deliver actionable process parameters or direct process control actions.
“Traditional Raman-based analyzers require a sharp learning curve for the user which is time-consuming for initial model building and continued model updates,” said Dr. Seongkyu Yoon, professor in the Department of Chemical Engineering and the Ward Endowed Professor in Biomedical Sciences at the University of Massachusetts-Lowell, in a press release. “With MAVERICK, all the hurdles of traditional Raman have been overcome. This device provides very good measurements independently of cell line, media, and scale, which is very beneficial.”
According to the press release, the MAVERICK hub can monitor up to six bioreactor modules simultaneously, with independent analog or digital control of feed systems for each. Further, remote real-time web access to bioreactor status and settings is supported through the MAVERICK hub. This type of device will enhance biopharmaceutical process development and manufacturers’ ability to implement dynamic control strategies at a faster pace.
“As the biopharmaceutical industry adopts Process Analytical Technologies to drive the advancement of Biopharma 4.0, scientists need an array of tools that enable them to monitor and control their process in real time,” said Christopher D. Brown, chief product officer and co-founder of 908 Devices, in a press release. “We are addressing this need with our full complement of devices. With MAVERICK, we are introducing a new platform that offers easy-to-integrate in-line analysis and control without the need for substantial expert configuration or set-up. In addition, as a spectroscopic-based device, MAVERICK is extensible to other analytes and parameters.”
Source: 908 Devices